Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Acquires 3,912 Shares of Becton, Dickinson and Company $BDX

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lifted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 79.5% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 8,832 shares of the medical instruments supplier’s stock after buying an additional 3,912 shares during the quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Becton, Dickinson and Company were worth $1,647,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Tema Etfs LLC lifted its holdings in shares of Becton, Dickinson and Company by 205.3% during the third quarter. Tema Etfs LLC now owns 7,444 shares of the medical instruments supplier’s stock worth $1,393,000 after buying an additional 5,006 shares in the last quarter. Citizens & Northern Corp boosted its holdings in Becton, Dickinson and Company by 2.8% in the 3rd quarter. Citizens & Northern Corp now owns 6,756 shares of the medical instruments supplier’s stock valued at $1,265,000 after purchasing an additional 187 shares during the period. Forum Financial Management LP grew its position in shares of Becton, Dickinson and Company by 26.9% during the 3rd quarter. Forum Financial Management LP now owns 5,825 shares of the medical instruments supplier’s stock worth $1,090,000 after purchasing an additional 1,236 shares in the last quarter. Hemington Wealth Management raised its position in shares of Becton, Dickinson and Company by 43.9% in the third quarter. Hemington Wealth Management now owns 226 shares of the medical instruments supplier’s stock valued at $42,000 after buying an additional 69 shares in the last quarter. Finally, Sachetta LLC grew its position in Becton, Dickinson and Company by 9.0% during the third quarter. Sachetta LLC now owns 748 shares of the medical instruments supplier’s stock worth $140,000 after buying an additional 62 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Down 1.2%

NYSE BDX opened at $202.78 on Monday. Becton, Dickinson and Company has a 52 week low of $162.29 and a 52 week high of $251.99. The company has a market cap of $57.77 billion, a price-to-earnings ratio of 34.78, a P/E/G ratio of 2.24 and a beta of 0.23. The business has a 50 day moving average price of $193.11 and a 200-day moving average price of $188.36. The company has a quick ratio of 0.64, a current ratio of 1.11 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. The company had revenue of $5.32 billion for the quarter. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. As a group, equities analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, December 31st. Shareholders of record on Monday, December 8th were paid a dividend of $1.05 per share. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. The ex-dividend date was Monday, December 8th. This represents a $4.20 annualized dividend and a yield of 2.1%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 72.04%.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. Piper Sandler cut their target price on Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating for the company in a research report on Friday, November 7th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Bank of America increased their target price on shares of Becton, Dickinson and Company from $190.00 to $207.00 and gave the stock a “neutral” rating in a report on Monday, January 5th. Royal Bank Of Canada boosted their target price on shares of Becton, Dickinson and Company from $202.00 to $210.00 and gave the stock a “sector perform” rating in a research note on Wednesday, December 17th. Finally, Argus increased their price target on Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Four equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $207.64.

Insiders Place Their Bets

In other news, Director Bertram L. Scott sold 217 shares of the company’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $176.58, for a total value of $38,317.86. Following the completion of the sale, the director owned 35,816 shares in the company, valued at $6,324,389.28. This represents a 0.60% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Michael David Garrison sold 629 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $196.03, for a total value of $123,302.87. Following the sale, the executive vice president owned 13,105 shares in the company, valued at $2,568,973.15. This trade represents a 4.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 1,052 shares of company stock worth $201,235 over the last ninety days. Insiders own 0.40% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.